BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17081326)

  • 1. Sarcomatoid carcinoma with osseous differentiation in the bladder.
    Arenas LF; Fontes DA; Pereira EM; Hering FL
    Int Braz J Urol; 2006; 32(5):563-5. PubMed ID: 17081326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [International Consensus Panel--treatment strategies for superficial bladder cancer].
    Adler S; St Niclas M
    Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
    [No Abstract]   [Full Text] [Related]  

  • 3. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer--resection/ablation.
    Corica FA; Keane TE
    Surg Oncol Clin N Am; 2005 Apr; 14(2):321-52. PubMed ID: 15817242
    [No Abstract]   [Full Text] [Related]  

  • 9. The nested variant of bladder transitional cell carcinoma: Review of 12 cases and review of the literature.
    Carrion-Ballardo CJ; Gala-Solana L; Portillo-Martin JA; Azueta-Etxebarria A; Truan-Cacho D; Campos-Juanatey F
    Actas Urol Esp; 2015; 39(6):387-91. PubMed ID: 25670479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacillus Calmette-Guérin treatment of urothelial carcinoma arising in the ileal neobladder after radical cystectomy.
    Yamashita R; Matsuzaki M; Niwakawa M; Ito I
    Int J Urol; 2014 Mar; 21(3):333-4. PubMed ID: 23991753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    Int Braz J Urol; 2019; 45(2):315-324. PubMed ID: 30785697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pure squamous cell carcinoma after intravesical BCG treatment. A case report.
    Yurdakul T; Avunduk MC; Piskin MM
    Urol Int; 2005; 74(3):283-5. PubMed ID: 15812221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncological outcome of radical cystectomy for BCG failure compared to primary invasive disease].
    Masson-Lecomte A; Vordos D; Yiou R; Allory Y; Abbou C; de la Taille A; Salomon L
    Prog Urol; 2013 Jun; 23(7):456-63. PubMed ID: 23721705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sarcomatoid carcinoma of the urinary bladder: report of a case].
    Kawamura N; Kakuta Y; Fukuhara S; Imazu T; Hara T; Yamaguchi S; Adachi S
    Hinyokika Kiyo; 2007 Oct; 53(10):713-6. PubMed ID: 18018588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
    Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
    BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.